drugset / Trial / NCT06132893

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893 ↗

Phase 2/3 Recruiting 390 enrolled Biohaven Therapeutics Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Timeline

Start
2024-03-14
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BHV-7000 Unknown 25 mg —
Subject BHV-7000 Unknown 50 mg —
Subject BHV-7000 Unknown 75 mg —

Indications